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Abstract A squamous cell carcinoma antigen (SSCA), which is 
a member of the serpin family of proteinase inhibitors, was puri- 
fied from sera of cancer patients. It did not inhibit serine pro- 
teinases. However, it non-competitively inhibited human cathep- 
sin L with a K i of 0.064 nM, but not cathepsins B and H among 
cysteine proteinases. These results indicated that SCCA is a 
non-functional serpin that inhibits cathepsin L in cancer cells. 
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porcine pancreas, thrombin, plasmin, plasminogen a d kallikrein from 
human plasma, urokinase from human urine, papain (2× crystallied) 
from papaya latex were purchased from Sigma Chemical Co. (St. Louis, 
MO, USA). Tissue plasminogen activator was obtained from Cappel 
Products (USA). Human cathepsin G was from Cosmo Bio Co. 
(Tokyo, Japan). t-Butyloxycarbonyl (Boc)-Phe-Ser-Arg-4-methyl- 
coumaryl-7-amide (MCA), Boc-Val-Pro-Arg-MCA, Boc-Val-Leu-Lys- 
MCA, succinyl (Suc)-Leu-Leu-Val-Tyr-MCA, carbobenzoxy (Z)-Gly- 
GIy-Arg-MCA, Z-Arg-Arg-MCA, Z-Phe-Arg-MCA, N-methoxysuc- 
cinyl(Suc(OMe))-Ala-Ala-Pro-Val-MCA andArg-MCA were products 
of the Peptide Institute Inc. (Osaka, Japan). Suc-AIa-AIa-Phe-MCA 
was from Enzyme System Product Inc. (USA). 
1. Introduction 
Squamous cell carcinoma ntigen (SCCA) is a protein iso- 
lated from human uterine cervical SCC tissue [1-3] that is 
widely used for the diagnosis and management of SCC [4-6]. 
In addition, serum SCCA levels are elevated in inflammatory 
dermatoses with eczema nd psoriasis [7]. The leakage of SCCA 
into body fluids from SCC tissues is apparently influenced by 
the infiltrative growth and the degree of histologic differentia- 
tion of tumor cells [8]. However, the function of SCCA in tumor 
cells remains unknown. Proteolytic mechanisms have been im- 
plicated in tumor cell metabolism and invasion [9-14]. The 
cDNA of SCCA has been cloned by Suminami et al. [15] and 
the deduced amino acid sequence revealed ideal homology with 
the serpin family of proteinase inhibitors. Takahashi et al. [16] 
have purified a high molecular mass cysteine proteinase inhib- 
itor (psoriastatin) from psoriatic scale, and demonstrated its 
strong immunoreactivity to an antibody against SCCA. 
Here, we describe that SCCA isolated from sera of cancer 
patients specifically inhibits lysosomal cysteine proteinase 
cathepsin L. 
2. Materials and methods 
2.1. Materials 
Cathepsins B, H, and L were prepared from autopsied human liver 
samples as described [17]. Trypsin, ~-chymotrypsin a d elastase from 
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Abbreviations." SCCA, squamous cell carcinoma ntigen; FPLC, fast 
protein liquid chromatography; HPLC, high performance liquid 
chromatography; Boc, t-butyloxycarbonyl; Suc, succinyl; Z, carboben- 
zoxy; Suc(OMe), N-methoxysuccinyl; MCA, 4-methylcoumaryl-7- 
amide; DTT, dithiothreitol; SDS, sodium dodecyl sulfate. 
2.2. Preparation of SCCA 
SCCA positive sera from patients with lung or uterine cervical cancer 
were obtained from Fujigaoka Hospital Central Laboratory. SCCA 
was isolated from pooled sera (about 600 ml), dialyzed against 0.5 M 
NaC1 in 20 mM Tris-HCl buffer, pH 7.5, and purified on anti-psoria- 
statin IgG-Sepharose 4B column (3 x 1 cm) prepared according to the 
protocol supplied by Pharmacia. The SCCA fraction dialyzed against 
25 mM acetate buffer, pH 5.0, was applied to a Mono S column 
equilibrated with same buffer equipped with a fast protein liquid 
chromatography (FPLC) System (LKB-Pharmacia, Sweden). The pro- 
teins were eluted with a linear gradient of 0 to 0.45 M NaC1. The SCCA 
fraction was dialyzed against Polybuffer 92, adjusted to pH 8.5, then 
applied to a Mono P column. The proteins were eluted by Polybuffer 
pH gradient from pH 8.0 to 4.5. The SCCA fraction was concentrated 
by ultrafiltration with an Amicon PM-10 membrane. The concentrate 
was filtered by HPLC on a G3000SW column equilibrated with the 
starting buffer. The SCCA fraction was further purified by a 2nd FPLC 
on Mono S as shown in Fig. 1. The preparation was apparently homog- 
enous on SDS-PAGE. SCCA was detected and the concentration was 
determined using an IMx-SCC test kit (DaiNabot Co., Japan). 
2.3. Inhibitory assays 
Boc-Phe-Ser-Arg-MCA, Suc-Leu-Leu-Val-Tyr-MCA, Boc-Val-Pro- 
Arg-MCA, Z-Gly-GIy-Arg-MCA, Suc(OMe)-Ala-Ala-Pro-VaI-MCA, 
Suc-AIa-Ala-Phe-MCA, Z-Arg-Arg-MCA and Arg-MCA were the 
substrates for trypsin, ~-chymotrypsin, thrombin, urokinase, lastase, 
cathepsin G, cathepsin B and cathepsin H, respectively. Z-Phe-Arg- 
MCA was the substrate for cathepsin (B + L), papain and kallikrein. 
Boc-Val-Leu-Lys-MCA was the substrate for plasmin and plasminogen 
activator. All substrates were dissolved in 0.05% Brij 35. Proteinases 
were incubated for 5 rain at 25°C with increasing amounts of SCCA 
before the reaction was started by adding 10/tl of substrate. The 
amount of MCA liberated from the substrates was determined fluoro- 
metrically with excitation and emission wavelengths of 360 and 460 nm, 
respectively, using a Hitachi fluorescence spectrophotometer, model 
MPF-750. The buffers were (i) 0.1 M Tris-HCl, pH 7.5, containing 10 
mM CaC12 for trypsin, kallikrein, plasmin and plasminogen activator, 
(ii) 0.1 M Tris-HC1, pH 8.0, containing 10 mM CaCI 2 for ~-chymotryp- 
sin, (iii) 0.1 M phosphate buffer, pH 6.8, containing 1 mM EDTA and 
4 mM dithiothreitol (DTT) for papain, cathepsin B and cathepsin H, 
(iv) 0.1 sodium acetate buffer, pH 5.5, containing 1 mM EDTA and 
4 mM DTT for cathepsin L, and (v) 0.1 M phosphate buffer, pH 7.0 
for elastase and cathepsin G. The inhibition constant (Ki) was calcu- 
lated according to the method of Dixon [18]. 
0014-5793195/$9.50 © 1995 Federation of European Biochemical Societies. All rights reserved. 
SSDI  0014-5793(94)01456-6 
A. Takeda et al. IFEBS Letters 359 (1995) 7880 79 
E 0.15 
N mo 
t- 
O 
O 0 
kDa i 
97- '1  
66-  
i 
31-  
20-  
10 
Fract ion  
Y 
20 30 
number (1 ml / tube) 
100 
-Q2 
T 
I 
50~ .. 
3 
< 
U 
U 
0 -0 
Fig. 1. The 2nd FPLC of SCCA on a Mono S column. The SCCA 
fraction from HPLC on G3000SW was dialyzed against a 25 mM 
acetate buffer, pH 5.0, and applied to a Mono S column. The fraction 
was eluted at a flow rate of 1 ml/min with a linear gradient of 0 to 0.45 
M NaCI in the same buffer. (Insert) SDS-PAGE of SCCA. Electropho- 
resis was performed by Laemmli's method using a 12.5% gel and the 
protein (0.6 #g) was stained with Coomassie brilliant blue. 
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Fig. 2. Kinetic analysis of the reaction of cathepsin L with SCCA. 
Lineweaver-Burk plot of the substrate (Z-Phe-Arg-MCA) concentra- 
tion against cathepsin L activity in the presence (©, 0.142 pM) or 
absence (e) of SCCA. 
3. Results and discussion 
We used an anti-psoriastatin a tibody (IgG) as a ligand for 
affinity chromatography to isolate SCCA from the sera of can- 
cer patients. The total SCCA in sera was adsorbed onto the 
column. The final yield of SCCA was about 37%. SCCA mi- 
grated as a single protein band with molecular mass of 45 kDa 
on SDS-PAGE (Fig. 1). The inhibitory ability of this prepara- 
tion towards erine and cysteine proteinases was measured. The 
results are summarized in Table 1. Although the amino acid 
sequences around the reactive site loop of serpins is homolo- 
gous with that of SCCA [13], the latter did not inhibit serine 
proteinases. SCCA specifically inhibited cathepsin L and pa- 
pain but not cathepsins B and H, which are all cysteine pro- 
teinases. The inhibition was independent of the preincubation 
time of the mixture of SCCA and proteinase. A Lineweaver- 
Burk plot showed that SCCA non-competitively inhibited 
cathepsin L with a Ki value of 0.064 nM (Fig. 2). 
There are at least sixteen families of serine proteinase inhib- 
itors and most of them obey the 'canonical' mechanism of 
Table 1 
Inhibitory activities of SCCA on serine and cysteine proteinases 
Proteinases Inhibitory activity (%) 
Trypsin N.I. 
Cymotrypsin N.I. 
Thrombin N.I. 
Plasmin N.I. 
Urokinase N.I. 
Plasminogen activator N.I. 
Elastase N.I. 
Cathepsin G N.I. 
Cathepsin B N.I. 
Cathepsin H N.I. 
Cathepsin L 78 
Papain 80 
Inhibition assays were performed as described insection 2. The reaction 
mixture was incubated for 5 min at 25°C at a SCCA:proteinase ratio 
of 3.7 : 1 (mol/mol). N.I., not inhibited. 
inhibition [19,20]. The target proteinase specificity of inhibitory 
serpins is determined by the nature of the reactive site peptide 
bond (P1-PI'). The P1-PI'  bond, Ser-Ser, of SCCA, which has 
yet to be found in other members of the serpin family, was not 
a reactive site for serine proteinases. There are non-functional 
serpins, which have structural variations uch as the exposed 
helix in intact ovalubumin [21] and the extreme form of loop 
insertion in latent plasminogen activator inhibitor-I [22]. The 
reason why SCCA was non-functional may be explained by the 
presence of structural variations that prevent he reactive site 
peptide bond being susceptible to serine proteinases. 
Recently, it has been reported that cytokine response modi- 
fier A (CrmA), one of the serpins, inhibited an interleukin-lfl 
converting enzyme, a member of a new family of cysteine pro- 
teinases [23]. SCCA significantly inhibited cathepsin L with a 
Ki value similar to that of two specific protein proteinase inhib- 
itors of the enzyme, cystatins and cathelin [24,25]. Although the 
active site of SCCA towards cysteine proteinases can not be 
determined based upon the information of sequence homology 
available, and its inhibition mechanism remains to be estab- 
lished, the above evidence indicates another example of 'cross- 
class' interaction between a proteinase and its inhibitor. The 
role of SCCA is still unknown. Cathepsin L is synthesized in
large amounts and secreted by many malignantly transformed 
cells in vitro [26] and the elevated expression of cathepsin L is 
associated with malignancy in several types of human cancer 
[27]. The results reported here suggested that SCCA is an im- 
portant regulator of cathepsin L activity in the malignant be- 
havior of tumor cells. 
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